While the 51.7% versus 47.4% is pretty close to equilibrium, any future growth in Mavyret's new patient share might entice Gild to change their pricing strategy to maintain market share.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.